For most investors, Vaxxas has been “the one that got away”, with $100 million of the equity raised to date split between ...

Genentech, the biotech unit of Swiss major Roche, has been marketing lung cancer drugs for nearly two decades, starting with ...

Taiwan should seek to tackle the dual challenges of low birthrates and talent shortages by adopting innovative policies and ...

Yale spinout Modifi has agreed to sell to Merck for $30 million upfront. Elsewhere, Sangamo plotted a much faster path to ...

Modifi Biosciences, a New Haven startup biotech that focuses on developing cancer therapies, has been acquired by ...

Merck (NYSE:MRK) has acquired Modifi Biosciences, a developer of DNA modification-enabled cancer drugs, for $30M upfront and ...

In a report released today, Akash Tewari from Jefferies maintained a Buy rating on Merck & Company (MRK – Research Report), with a ...

Modifi Biosciences announced that the company has been acquired by Merck (MRK). Under the terms of the agreement Merck, through a subsidiary, ...

Merck has acquired Modifi Biosciences for as much as $1.3 billion, gaining access to its experimental cancer therapies, the ...

Merck & Co. has acquired Modifi Biosciences, a developer of cancer therapies that was spun out of Yale University, in a deal potentially worth more than $1 billion.

Shawn Li, principal scientist at Merck & Co., known as MSD outside the Unites States and Canada, talked about the importance ...

Merck has acquired Modifi Biosciences for as much as $1.3 billion, gaining access to its experimental cancer therapies, the ...